EDAP to Present at Jefferies Global Healthcare Conference in London
EDAP to Present at Jefferies Global Healthcare Conference in London
Company to Present and Host 1x1 Investor Meetings on Tuesday, November 18th, 2025
AUSTIN, Texas, November 4, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and host 1x1 investor meetings at the upcoming Jefferies Global Healthcare Conference, which is being held November 18-20, 2025, in London, United Kingdom.
Date: Tuesday, November 18th
Presentation Time: 4:30-4:55 pm GMT
Format: Presentation and 1x1 investor meetings
Location: Waldorf – Aldwych, Entresol Level
Webcast: https://wsw.com/webcast/jeff332/edap/1817998
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
legal@focalone.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
